non-atrophic gastritis(=chronic superficial gastritis)(CSG)
Conditions
Interventions
Placebo-controlled group:Sanjiu weitai granules placebo,2.5g,bid]+[Teprenone Capsules placebo,50mg,tid]
Positive drug controlled group:Sanjiu weitai granules placebo,2.5g,bid]+[Teprenone Capsules placebo,50mg,tid]
Experimental group:[Sanjiu weitai granules,2.5g,bid]+[Teprenone Capsules placebo,50mg,tid]
Sponsors
Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1 .Male and female aged 18 to 70 years old. 2. fulfill the diagnostic criteria of non-atrophic gastritis in Western Medicine,and meet at least one of the following: (1) erythema ranked as grade 2 and above; (2) with erosive; (3) with mucous membrane bleeding. 3. fulfill the diagnostic criteria of TCM syndrome patterns as follows: syndrome of dampnessheat of spleen and stomach,syndrome of incoordination beteeen liver and stomach,syndrome of deficiency of stomach yin, syndrome of deficiency of stomach and spleen qi, syndrome of static blood in stomach collaterals,syndrome of deficient cold of spleen and stomach; 4. sign the informed consent and will to accept corresponding intervention; 5. have the ability of reading power.
Exclusion criteria
Exclusion criteria: 1. merge with diseases of active peptic ulcer,gastritis with active bleeding,severe dysplasia or suspected malignancy of the gastric mucosa; 2. diagnosed atrophic gastritis by pathology; 3. a history of gastric surgery; 4. long-term use of hormones, NSAIDs; 5. have used treatment medicines of the disease in the nearly two weeks after the onset of the disease and do not allow entering a 2-week drug washout period because of the disease condition or individuals unwilling; 6. has a serious primary cardiovascular disease, liver disease, kidney disease, hematologic disease, lung disease, or other serious diseases affected the survival, such as cancer or AIDS; 7. mental illness and intellectual, language disabilities; 8. pregnant or lactating women; 9. be allergy to the drug composition used in the trial; 10. patients who is participating or participated in last 4 weeks in other drug clinical trials; 11. suspected or indeed alcohol or drug abuse history, or possibility of easily being lost according to the researchers' determination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mucosal lesion score under endoscopy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom score;Score of Patient reported outcome instrument; | — |
Countries
China
Contacts
Public ContactXudong Tang
Outcome results
None listed